CWA Asset Management Group LLC Raises Stock Holdings in United Therapeutics Corporation (NASDAQ:UTHR)

CWA Asset Management Group LLC raised its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 51.6% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,224 shares of the biotechnology company's stock after buying an additional 2,799 shares during the period. CWA Asset Management Group LLC's holdings in United Therapeutics were worth $2,535,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of UTHR. Dunhill Financial LLC boosted its holdings in United Therapeutics by 100.0% during the 4th quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company's stock valued at $35,000 after acquiring an additional 50 shares during the period. Sound Income Strategies LLC bought a new stake in shares of United Therapeutics during the first quarter worth $49,000. State of Wyoming purchased a new stake in shares of United Therapeutics during the fourth quarter valued at $62,000. Curat Global LLC bought a new position in shares of United Therapeutics in the first quarter worth about $63,000. Finally, Millstone Evans Group LLC bought a new position in shares of United Therapeutics in the fourth quarter worth about $67,000. Institutional investors own 94.08% of the company's stock.

Insider Activity

In related news, Director Tommy G. Thompson sold 2,500 shares of the stock in a transaction that occurred on Monday, March 24th. The shares were sold at an average price of $318.80, for a total transaction of $797,000.00. Following the completion of the sale, the director now owns 8,480 shares of the company's stock, valued at $2,703,424. This represents a 22.77% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO James Edgemond sold 12,000 shares of the firm's stock in a transaction that occurred on Monday, June 9th. The shares were sold at an average price of $325.37, for a total transaction of $3,904,440.00. Following the completion of the sale, the chief financial officer now owns 8,118 shares of the company's stock, valued at approximately $2,641,353.66. This trade represents a 59.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 79,500 shares of company stock worth $23,907,950. Corporate insiders own 10.30% of the company's stock.

United Therapeutics Trading Up 1.7%

Shares of NASDAQ:UTHR traded up $4.84 on Thursday, reaching $291.72. The company had a trading volume of 641,277 shares, compared to its average volume of 452,753. The firm has a market capitalization of $13.16 billion, a PE ratio of 11.64, a PEG ratio of 6.28 and a beta of 0.57. United Therapeutics Corporation has a 52-week low of $266.98 and a 52-week high of $417.82. The firm's 50 day simple moving average is $300.54 and its 200-day simple moving average is $329.07.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share for the quarter, beating analysts' consensus estimates of $6.29 by $0.34. The company had revenue of $794.40 million for the quarter, compared to the consensus estimate of $726.82 million. United Therapeutics had a return on equity of 19.33% and a net margin of 40.44%. The firm's revenue for the quarter was up 17.2% compared to the same quarter last year. During the same quarter last year, the company earned $6.17 earnings per share. As a group, equities research analysts predict that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. Wells Fargo & Company reissued an "equal weight" rating and issued a $314.00 price objective (down from $395.00) on shares of United Therapeutics in a research report on Friday, April 25th. Cantor Fitzgerald assumed coverage on shares of United Therapeutics in a research note on Monday, June 2nd. They set an "overweight" rating and a $405.00 price target for the company. JPMorgan Chase & Co. dropped their price objective on United Therapeutics from $355.00 to $350.00 and set an "overweight" rating on the stock in a research note on Thursday, May 1st. HC Wainwright restated a "buy" rating and set a $425.00 price objective on shares of United Therapeutics in a report on Monday, May 5th. Finally, Morgan Stanley upped their target price on United Therapeutics from $346.00 to $348.00 and gave the stock an "equal weight" rating in a report on Thursday, May 1st. Four investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $393.08.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.